Scout | RFA-NS-24-019: HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

This opportunity is no longer accepting applications.

grant RFA-NS-24-019

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Summary

This grant opportunity is designed to fund the improvement and development of therapies that are safe, effective, and non-addictive for treating pain. It aims to speed up the advancement of promising drug candidates, both small molecule and biologic, towards clinical trials. To be eligible, applicants must have a promising drug candidate, a strong scientific basis for their approach, and suita…

Reissue of RFA-NS-20-010: The purpose of this funding opportunity announcement (FOA) is to support preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. The goal of the program is to accelerate the optimization and …

Funding Source

Agency: National Institutes of Health

Sub-agency: National Institute of Neurological Disorders and Stroke

Dates

Opportunity Released: October 31, 2023

Open for Submission: October 31, 2023

Submission Deadline: January 7, 2027

Application Window Closes: January 7, 2027

Supporting links

National Institutes of Health

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers